

## REMARKS

The claims have been amended to conform to U.S. practice.


Reconsideration of the separation of Groups I and II is respectfully requested. Clearly thromboembolic disorders would benefit from inhibiting thrombosis and inhibiting platelet aggregation. No undue burden of searching the invention of both Groups I and II seems apparent. Therefore, applicants respectfully request that this aspect of the restriction requirement be reconsidered and Groups I and II examined in the same application.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. 205032000420.

Respectfully submitted,

Dated: October 10, 2002

By:

  
Kate H. Murashige  
Registration No. 29,959

Morrison & Foerster LLP  
3811 Valley Centre Drive,  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-5112  
Facsimile: (858) 720-5125

## **EXHIBIT A. - VERSION WITH MARKINGS TO SHOW CHANGES MADE**

### **In the Claims:**

1. (Amended) A method for inhibiting platelet aggregation in a mammal [including human], comprising administering to the mammal [including human] an effective amount of adenosine.
2. (Amended) A method for inhibiting thrombosis in a mammal [including human], comprising administering to the mammal [including human] an effective amount of adenosine.
3. (Amended) A method for preventing and treating thromboembolic disorders in a mammal [including human], comprising administering to the mammal [including human] an effective amount of adenosine.
10. (Amended) A pharmaceutical composition for inhibiting platelet aggregation in a mammal [including human], comprising an effective amount of adenosine and a pharmaceutically acceptable carrier or diluent.
11. (Amended) A pharmaceutical composition for inhibiting thrombosis in a mammal [including human], comprising an effective amount of adenosine and a pharmaceutically acceptable carrier or diluent.
12. (Amended) A pharmaceutical composition for treating thromboembolic disorders in a mammal [including human], comprising an effective amount of adenosine and a pharmaceutically acceptable carrier or diluent.
16. (Amended) A kit for inhibiting platelet aggregation and thrombosis in a mammal [including human], comprising a first container containing adenosine and a second container containing a pharmaceutically acceptable carrier or diluent.

17. (Amended) A kit for inhibiting platelet aggregation and thrombosis in a mammal [including human], comprising a first container containing adenosine, a second container containing an antithrombotic, and a third container containing a pharmaceutically acceptable carrier or diluent.